Fig. S6.

T-cell proliferation and activation states in Gl261 tumors do not change under treatment. In all panels, IgG, n = 6; B20, n = 6; A2V, n = 5. (A and B) Proliferating CD4⁺ cells were identified by gating through CD4⁺/Thy1⁺/Ki-67, and no differences between the treatment groups were measured. (C and D) CD4⁺/Thy1⁺/CD44⁺/Ki-67–activated and proliferating CD4⁺ T cells were unchanged by treatment. (E–H) Gating through CD8⁺/Thy1⁺/Ki-67 (E and F) and CD8⁺/Thy1⁺/CD44⁺/Ki-67 (G and H) showed no difference in CD8⁺ T-cell proliferation or activation.